Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Pinterest Inc (PINS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Pinterest Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Pinterest Inc trades at $22.66 (market cap $12.61B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 3.2× Pinterest Inc's market cap, and Pinterest Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | PINS | |
|---|---|---|
Market Cap | $39.89B | $12.61B |
Sector | Health | Media |
52-Week High | $491.22 | $39.17 |
52-Week Low | $278.09 | $15.42 |
Enterprise Value | $38.15B | $12.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Pinterest (PINS) trades at $22.53, down 0.71% on the day, with a bullish technical outlook supported by moving averages. The company reported revenue growth to $4.22B in 2025, with net income of $416.86M and a net margin of 9.87%. Recent news highlights AI-driven shopping initiatives and strong user growth, while analyst sentiment remains positive with a consensus price target of $27.72.
The stock presents a growth opportunity with improving profitability and strategic AI investments, but faces risks from competitive pressure and valuation concerns. Wall Street's bullish consensus suggests upside potential, though investors should monitor execution on monetization and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Pinterest Inc
Pinterest is an online product and idea discovery platform that helps users gather ideas on everything from recipes to cook to destinations to travel to. Founded in 2010, the platform consists of a largely female audience, at roughly two thirds of its more than 365 million monthly active users. The company generates revenue by selling digital ads and is now rolling out more in-platform e-commerce features.
Read more on PINS →
